Loading…
CG Oncology, Inc. is projected to rise to $109.87 by 2027, a +50% move from its current price of $73.03. CGON is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $70.98 | $73.08 | $75.24 | +0.06% |
| Aug 2 | $70.18 | $73.12 | $76.20 | +0.13% |
| Aug 3 | $69.57 | $73.17 | $76.96 | +0.19% |
| Aug 4 | $69.08 | $73.22 | $77.61 | +0.26% |
| Aug 5 | $68.65 | $73.27 | $78.19 | +0.32% |
| Aug 6 | $68.27 | $73.31 | $78.73 | +0.39% |
| Aug 7 | $67.92 | $73.36 | $79.23 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $67.92 | $73.36 | $79.23 | +0.45% |
| Week 2 | $66.09 | $73.70 | $82.17 | +0.91% |
| Week 3 | $64.79 | $74.03 | $84.59 | +1.37% |
| Week 4 | $63.75 | $74.37 | $86.75 | +1.83% |
| Week 5 | $62.89 | $74.70 | $88.74 | +2.29% |
| Week 6 | $62.14 | $75.04 | $90.62 | +2.76% |
| Week 7 | $61.49 | $75.38 | $92.42 | +3.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CG Oncology, Inc. is a healthcare company focused on bladder cancer therapies. It develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure and in phase 3 trials to evaluate safety and efficacy in various BCG-unresponsive NMIBC settings. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc.
in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
CG Oncology, Inc. (CGON) is currently trading at $69.32. It has a market capitalization of $6.11B and is ranked 1167.
A major floor 26.4% below — a decisive break under it would weaken the trend.
The nearest floor, 17.3% below — buyers have tended to step in here.
The nearest ceiling, 3.0% above — a clean break opens room to run.
A major ceiling 15.5% above — clearing it would confirm fresh momentum.
Key CGON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.52 | Buy | $71.61 | Buy |
| MA 10 | $71.18 | Buy | $71.37 | Buy |
| MA 20 | $71.29 | Buy | $70.60 | Buy |
| MA 50 | $65.86 | Buy | $68.11 | Buy |
| MA 100 | $66.53 | Buy | $64.66 | Buy |
| MA 200 | $56.65 | Buy | $57.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.60 | Neutral |
| Stoch RSI (14) | 54.21 | Neutral |
| CCI (20) | 74.02 | Neutral |
| Williams %R (14) | -11.14 | Info |
| MACD (12,26,9) | -0.28 | Sell |
| ROC (12) | 1.76 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 88.86 | Sell |
| TRIX (15) | 0.36 | Buy |
| Awesome (5,34) | 2.54 | Buy |
| Ultimate (7,14,28) | 52.51 | Neutral |
| Momentum (10) | 3.53 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 71.99 | Buy |
| ADX (14) | 14.81 | Neutral |
| ATR (14) | 2.14 | Info |
The technical picture is bullish by category, with RSI14 at 50 and the stock trading above key averages. The SMA50 is $65.62 and the SMA200 is $55.89, suggesting the near-term trend is constructive. The stock sits near a support of $54.92 and a resistance of $75.24, with the thirty-day range spanning from $58.53 to $82.11.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $40.04 | $73.03 | $105.58 | 0% | Neutral | |
| $87.09 | $109.87 | $146.87 | +50% | Bullish | |
| $91.56 | $119.06 | $165.60 | +63% | Bullish | |
| $99.63 | $132.85 | $190.56 | +82% | Bullish | |
| $112.56 | $153.45 | $225.87 | +110% | Bullish | |
| $114.86 | $159.78 | $240.52 | +119% | Bullish | |
| $138.28 | $195.99 | $301.03 | +168% | Bullish | |
| $168.84 | $243.57 | $380.97 | +234% | Bullish | |
| $182.21 | $267.31 | $425.14 | +266% | Bullish | |
| $207.31 | $309.05 | $499.21 | +323% | Bullish | |
| $301.64 | $483.76 | $833.68 | +562% | Bullish | |
| $499.85 | $910.01 | $1,722.71 | +11.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $40.04 | $73.03 | $85.20 | +0.00% |
| August 2026 | $63.95 | $75.16 | $90.47 | +2.91% |
| September 2026 | $65.33 | $77.47 | $94.59 | +3.08% |
| October 2026 | $64.66 | $77.22 | $95.35 | -0.33% |
| November 2026 | $65.74 | $78.98 | $98.40 | +2.28% |
| December 2026 | $69.58 | $84.04 | $105.58 | +6.42% |
Click any year to see its month-by-month CGON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CG Oncology, Inc.'s 2026 outlook centres on $73.03, within a $40.04 to $105.58 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CGON could reach as high as $146.87, with a base case around $109.87 and support toward $87.09 — roughly +50% from $73.03. Buyers look set to stay in control over this stretch.
Expect CGON to range from $91.56 to $165.60 through 2028. The $119.06 average target implies a +63% move from current prices. That is up +8% on the projected 2027 average. Momentum favours further upside here.
The CGON price prediction for 2029 points to an average of $132.85 (low $99.63, high $190.56) — a potential gain of +82% on today's $73.03. Buyers look set to stay in control over this stretch.
In 2030, CGON is projected to trade between $112.56 and $225.87, averaging $153.45 — a potential gain of +110% from today's $73.03. That is up +16% on the projected 2029 average. Momentum favours further upside here.
CG Oncology, Inc.'s 2031 outlook centres on $159.78, within a $114.86 to $240.52 range. That is up +4% on the projected 2030 average. That marks a +119% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CGON could reach as high as $301.03, with a base case around $195.99 and support toward $138.28 — roughly +168% from $73.03. Momentum favours further upside here.
Expect CGON to range from $168.84 to $380.97 through 2033. The $243.57 average target implies a +234% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CGON price prediction for 2034 points to an average of $267.31 (low $182.21, high $425.14) — a potential gain of +266% on today's $73.03. Momentum favours further upside here.
In 2035, CGON is projected to trade between $207.31 and $499.21, averaging $309.05 — a potential gain of +323% from today's $73.03. That is up +16% on the projected 2034 average. Buyers look set to stay in control over this stretch.
CG Oncology, Inc.'s 2040 outlook centres on $483.76, within a $301.64 to $833.68 range. That is up +57% on the projected 2035 average. That marks a +562% change versus current levels. Momentum favours further upside here.
By 2050, CGON could reach as high as $1,722.71, with a base case around $910.01 and support toward $499.85 — roughly +11.5x from $73.03. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGON today (≈ 13.693003 CGON) could be worth
$12,460.78
+$11,460.78 (+1146%) by 2050 · US Dollar
Based on the average projected CGON price of $910.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGONwould be worth at today's price.
$1,000 invested in CGON on Jul 30, 2025 (≈ 37.160907 CGON) would be worth
$2,713.86
+$1,713.86 (+171.4%) today · 2.71× · US Dollar
Based on a CGON entry price of $26.91 vs. today's $73.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.12 | $1,026.86 | +2.7% |
| 1 month ago | $71.05 | $1,027.87 | +2.8% |
| 3 months ago | $66.27 | $1,102.01 | +10.2% |
| 6 months ago | $52.05 | $1,403.07 | +40.3% |
| 1 year ago | $26.91 | $2,713.86 | +171.4% |
| All time (2.5y) ago | $37.17 | $1,964.76 | +96.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGON forecast.
Our base-case forecast reaches $150.00 around 2030.
Implied market cap at $150.00: $13.23B
The multi-year forecast shows a bullish trajectory with rising average prices in coming years. For 2026 the avg is $69.32 with min $40.04 and max $98.96 and neutral sentiment. From 2027 onward the Avg rises to $101.37 (min $81.25, max $133.47) with ROI 46.2 and bullish sentiment, followed by 2028 Avg $110.85 (min $86.54, max $151.21) ROI 59.9, 2029 Avg $123.62 (min $94.44, max $173.38) ROI 78.3, and 2030 Avg $141.33 (min $105.92, max $202.88) ROI 103.9 with bullish sentiment.
The forecast continues to escalate through 2031–2035, 2040 and 2050, with notable milestones such as 2031 Avg $148.71, 2032 Avg $179.21, 2033 Avg $218.98, 2034 Avg $241.53, 2035 Avg $276.64; 2040 Avg $428.35 (ROI 517.9) and 2050 Avg $809.94 (ROI 1068.4). These are estimates and not guarantees, and risks to the path include variability in clinical outcomes, regulatory decisions, and market dynamics.
Tap a question to reveal the answer.
Avg price $141.33; min $105.92; max $202.88; ROI 103.9; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising average prices and growing ROI (2027 ROI 46.2, 2028 ROI 59.9, 2029 ROI 78.3, 2030 ROI 103.9, 2040 ROI 517.9, 2050 ROI 1068.4). These are estimates, not guarantees.
Yes. The forecast’s 2033 max is $332.15, 2034 max is $371.96, and 2035 max is $432.09.
Current price $69.32; Market cap $6.11B.
The 30-day range is $58.53 to $82.11; RSI 14 is 50; SMA50 is $65.62; SMA200 is $55.89; Support is $54.92 and Resistance is $75.24; Annualized volatility is 50%.
CG Oncology, Inc. Community Discussion
0Share your CG Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.